Climate transformation is only going to increase the health equity divide. We're stepping up.

A clarion call to act

The evidence is clear and irrefutable - Earth's climate is undergoing a transformation. But most calls to alter our course before its too late get one fundamental thing wrong. The Earth will endure, just as it has weathered numerous extinction-level events before. It is life on Earth that is at risk, including our own.

We, the inhabitants of this planet, are the ones in danger. The Earth has experienced worse, but we have not. Our focus should not be on nature alone but on our survival. The question is not whether we care about the environment but whether we care about ourselves.

We are no longer preparing for a not-so-distant future.
We are in the future.

The WHO estimates that between 2030 and 2050, climate change is expected to cause approximately 250,000 additional deaths per year due to malnutrition, malaria, diarrhoea, and heat stress.

These health impacts will not be evenly distributed across the globe, with low-income countries and vulnerable populations being disproportionately affected. The healthcare crisis will only worsen with time—COPD, zoonotic diseases, heat strokes, pathogenic diseases —and the burden will be disproportionately borne by the poorest among us.

And Fabtech is stepping up to help the pharma industry tackle it now. We're committed to mitigating the fallout of the climate crisis. Our purpose is grounded in the belief that all lives hold equal value. Alongside our customers and partners, we're building pharmaceutical and biotech capabilities in regions that need it the most so that the most vulnerable among us have access to affordable, life-saving medicines.


From start to finish and everything in between

Our solutions help pharma and biotech companies solve problems big and small, complex and simple. Our emphasis on managing every stage of the project management cycle in-house ensures we deliver beyond expectation on every project - whether flexibility, operability or cost optimisation.

We’re stepping up to empower scientists, researchers, pharmacists, healthcare practitioners, governments and pharma companies to design new medicines and improve healthcare delivery systems with our efficient, sustainable start-to-finish solutions.

The world must not be blindsided again by whatever comes next.